Interventional Glaucoma

Q3 2026 delivered advances in some closely watched pipeline products.

Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.

The agency assigned a PDUFA target action date of April 30, 2027.

Large cohort links long-term tadalafil for urinary symptoms to modestly higher open-angle glaucoma risk.

A new study reported that the so-called “high-pillow sleeping position” can result in elevated intraocular pressure (IOP) values and decreased ocular perfusion pressure (OPP) in patients with glaucoma compared with sleeping in the supine position.

ZEISS CLINIC 360 is an all-in-one cloud and browser-based software platform designed to consolidate ophthalmic diagnostic and medical record data into a single, unified patient view.

CMS payment rates for the FSYX Ocular Pressure Adjusting Pump take effect October 1, 2026, clearing a reimbursement path for the noninvasive glaucoma device.

Host Deborah G. Ristvedt, DO, welcomes Dr. Berdahl to discuss the formative experiences, entrepreneurial drive, and personal philosophy that have shaped his career as a surgeon, innovator, and mentor.

AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

Glaukos finishes US pivotal enrollment for PRESERFLO MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

Rising star in Ophthalmology, Nicholas Riina, MS, focuses on artificial intelligence and uses robotics training to enhance glaucoma diagnosis.

The randomized, double-masked, 3-arm trial did not achieve its primary endpoint of replicating the visual function improvements observed in a smaller phase 1/2a study.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

Deeper anterior chamber depth and shorter disease course predicted better surgical outcomes

A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.

NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.

A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.

After accounting for key factors like eye length, researchers found no meaningful differences in corneal biomechanics between primary open-angle and primary angle-closure glaucoma.

The 17th European Glaucoma Society (EGS) Congress—being held in Brussels, Belgium, from 30 May to 2 June 2026—brings together glaucoma specialists across plenary sessions, hands-on surgical dry labs, national society symposia and cross-specialty debates.